MONARCH-3

NCT02246621 📎

Regimen

Experimental
Abemaciclib 150 mg BID continuously plus nonsteroidal AI (anastrozole or letrozole).
Control
Placebo plus nonsteroidal AI.

Population

Postmenopausal women with HR+/HER2- advanced breast cancer and no prior systemic therapy for metastatic disease.

Key finding

MONARCH-3 established abemaciclib plus nonsteroidal AI in 1L postmenopausal HR+/HER2- metastatic disease, with the longest median PFS among 1L CDK4/6 + AI trials. Final OS was a strong numerical trend but did not reach significance, contributing to nuanced cross-drug comparisons with MONALEESA-2.

Source: PMID 28968163

Timeline

  • Publication: 2017 Nov 10

Guideline citations

  • NCCN BREAST